Browse the evidence

Overall Venous Thromboembolism (VTE) risk is not significantly increased by GLP-1RA use, as the increase in DVT is offset by no change in Pulmonary Embolism (PE) risk.

Taking GLP-1 medications does not significantly increase your overall risk of blood clots (VTE) when looking at the big picture. While there is a small, non-significant upward trend, it is not statistically proven to be dangerous for the general population. The specific risk of DVT is only significant with very long-term use.

BMI is an inadequate and potentially harmful sole metric for assessing obesity severity and treatment response.

Do not rely on BMI alone. Your health is determined by your metabolic markers and fat distribution, not just your weight. Seek a comprehensive assessment that looks at your overall health risks.

GLP-1 medicines for obesity are predominantly tested in white/Caucasian populations (79%) with significant under-representation of non-white, Black, Asian, and Indigenous groups compared to their prevalence in multiethnic national populations.

Current GLP-1 obesity trials heavily feature white participants (79%). If you belong to a racial or ethnic minority, be aware that the standard dosing and efficacy data may not fully reflect your specific physiological response or risk profile. Advocating for or seeking out diverse clinical data is important for personalized care.

GLP-1 obesity trials are geographically concentrated in high-income countries (84.2% of sites), contrasting with the global prevalence of obesity which is highest in low- and middle-income countries (LMICs).

Most GLP-1 trials were conducted in high-income countries, yet most people with obesity live in low- and middle-income countries. This geographic gap means that treatment guidelines and availability may not reflect the needs of the majority of the global population.

SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors provide cardiovascular organ protection in type 2 diabetes through direct antioxidant and anti-inflammatory mechanisms, independent of glucose lowering.

If you have Type 2 Diabetes, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs do more than just lower blood sugar; they actively protect your heart and kidneys by reducing inflammation and oxidative stress, which are major drivers of heart disease in diabetic patients.

GLP-1 receptor agonists reduce platelet aggregation and thrombus formation, thereby mitigating the risk of thrombotic cardiovascular events in diabetic patients.

GLP-1 agonists may help prevent blood clots by making platelets less sticky, which adds to their heart-protective benefits beyond just sugar control.

Intestinal deficiency of Acyl-CoA synthetase 5 (ACSL5) reduces food intake and protects against diet-induced obesity by increasing postprandial secretion of GLP-1 and PYY.

This research suggests that how your body processes dietary fat in the intestine—specifically through the enzyme ACSL5—can influence your hunger hormones (GLP-1 and PYY). When this process is altered, it can lead to increased feelings of fullness and reduced food intake, potentially protecting against weight gain on high-fat diets. While this is a genetic mechanism in mice, it highlights the importance of gut hormones in regulating appetite and energy balance.

Semaglutide (2.4 mg weekly) induces MASH resolution in patients with stage 2-3 fibrosis, though it does not significantly improve fibrosis itself.

Semaglutide 2.4 mg weekly is highly effective at resolving active liver inflammation (MASH) in patients with moderate fibrosis. However, it does not reverse the scarring (fibrosis) itself. Patients should expect significant weight loss and metabolic improvement, but should not assume their liver scarring will disappear with this drug alone.

Statins reduce the risk of developing MASLD and progression to liver fibrosis, and may reduce cardiovascular events in MASLD patients, despite not directly reducing liver fat.

If you have fatty liver and high cardiovascular risk, you should take statins. They do not remove liver fat, but they reduce inflammation and fibrosis, and significantly lower your risk of heart attacks and strokes. The benefits outweigh the theoretical risks.

Pioglitazone improves MASH resolution and may improve fibrosis, but is limited by side effects like weight gain and heart failure exacerbation.

Pioglitazone can resolve MASH and improve fibrosis, but it causes weight gain and fluid retention, which can worsen heart failure. It is not a first-line treatment but may be considered if other options fail and heart failure is not a concern.

Once-weekly semaglutide treatment is associated with a significant increase in pulse rate compared to once-daily sitagliptin.

If you take semaglutide, expect your resting heart rate to increase slightly (by about 3 beats per minute) compared to if you took sitagliptin. This is a known side effect. While usually not dangerous, it is worth monitoring, especially if you have underlying heart conditions.

Semaglutide treatment is associated with a higher risk of total adverse events and premature treatment discontinuation compared to sitagliptin, although the risk of serious adverse events is not significantly different.

Be prepared for a higher likelihood of side effects and stopping the medication early when starting semaglutide compared to sitagliptin. Most side effects are gastrointestinal. Slow dose escalation can help. However, serious adverse events are not significantly more common with semaglutide.

Rapid and substantial weight reduction, such as that achieved by bariatric surgery or certain medications, may result in greater reductions in lean muscle mass compared to gradual weight reduction.

If you are undergoing rapid weight loss (e.g., surgery or strong medications), prioritize resistance training and adequate protein intake to protect your muscle mass. Monitor your body composition, not just scale weight, to ensure you are losing fat, not muscle.

GLP-1 receptor agonists increase the risk of gallbladder disease, including cholelithiasis and cholecystitis, through mechanisms involving cholecystokinin (CCK) suppression, altered bile acid receptor signaling (FXR/TGR5), and disrupted gut-brain pathways, leading to bile stasis and gallstone formation.

If you are taking a GLP-1 agonist (like semaglutide or liraglutide), be aware that you have a higher risk of gallbladder problems, especially if you are taking higher doses or losing weight rapidly. Watch for symptoms like severe abdominal pain, nausea, or fever, and report them to your doctor immediately. Your doctor may monitor you more closely or adjust your treatment plan to mitigate this risk.

Activation of brown and beige adipose tissue through pharmacological means (e.g., β3-AR agonists, GLP-1RAs) or transplantation improves glucose metabolism, insulin sensitivity, and energy expenditure, offering a therapeutic strategy for obesity and type 2 diabetes.

Your body has a biological mechanism to burn extra energy as heat using brown and beige fat. While cold exposure and exercise can activate this, pharmaceutical approaches (like mirabegron or GLP-1 agonists) are being studied to enhance this process. This suggests that metabolic health is not just about calories in/out but also about the activity of specific fat tissues.

Intensive dietary counseling targeting sodium reduction to <2.3 g/day fails to sustainably reduce sodium intake, blood pressure, or cardiorenal biomarkers in individuals with moderate baseline sodium intake over a two-year period.

If you currently eat a moderate amount of sodium (around 3 grams/day), trying to drastically cut it down to less than 2.3 grams through intense counseling is unlikely to work long-term. You might see a small, short-term drop in blood pressure, but it won't last, and it won't improve your heart or kidney health markers. The effort required to maintain such a low intake is likely too high for sustainable results in this group.

Adherence to liraglutide 3.0 mg for obesity treatment is extremely low (84.9% of patients exhibit low adherence), with only 15.1% achieving high adherence (PDC ≥80%) after 6 months.

If you are prescribed liraglutide 3.0 mg for weight loss, expect that most people stop taking it consistently within 6 months. High adherence (taking it daily as prescribed) is rare (15%). To succeed, you must actively manage side effects and address the burden of daily injections, possibly with dietitian support, as these are key predictors of sticking with the treatment.

Biased agonism of GLP-1R and GIPR (favoring cAMP over beta-arrestin recruitment) yields superior glucose lowering, food intake suppression, and weight loss compared to unbiased agonism.

Current GLP-1/GIP drugs that favor cAMP signaling (biased) appear to offer better and longer-lasting glucose control and weight loss than those that do not. This is likely due to the drug staying on the receptor longer without being internalized. While this is proven in mice, it suggests that drug design matters for efficacy, not just receptor activation.

AgRP neuron inhibition is a necessary mechanism for the appetite-suppressing effects of incretin-based obesity therapies (GLP-1 and GIP analogs).

This research confirms that GLP-1 and GIP medications (like Ozempic or Wegovy) work by directly inhibiting the brain's hunger-promoting neurons (AgRP). This neural inhibition is a key reason these drugs successfully suppress appetite.

GIP signaling is necessary for nutrient-mediated inhibition of AgRP neurons, whereas GLP-1 signaling is not.

This study reveals that GIP, not just GLP-1, is essential for your brain to register that you have eaten. This explains why drugs that activate both receptors (like Mounjaro/Zepbound) may be more effective than those activating only GLP-1.

GIPR signaling in the central nervous system (specifically GABAergic neurons) is required for the body weight-lowering effects of GIP-based therapies, whereas peripheral GIPR signaling in adipose tissue has complex, context-dependent effects on lipolysis vs lipogenesis.

GIP-based drugs work primarily by acting on the brain to reduce food intake, not just by affecting fat cells. This brain-based mechanism is why they are effective for weight loss even in non-diabetic individuals.

Lifelong endurance training preserves skeletal muscle oxidative capacity and capillarization in men aged 82-92, whereas physical function level does not correlate with these morphological markers.

For men in their 80s, maintaining a history of endurance training is associated with better muscle blood supply and energy production than simply being strong. While you cannot change your past, the data suggests that consistent aerobic activity preserves muscle quality better than inactivity, regardless of current strength levels.

Endurance training does not preserve satellite cell numbers or markers of muscle regeneration/denervation in very old men compared to sedentary peers.

Do not expect exercise to restore youthful muscle repair capabilities (satellite cells) in your 80s. While training improves blood flow and energy use, the cellular machinery for regeneration appears to decline with age regardless of activity level.

Dietary macronutrient composition (low-carbohydrate vs. low-fat) does not explain differences in ad libitum energy intake because the resulting changes in gut-derived appetite hormones (GLP-1, GIP, PYY, ghrelin) are insufficient to override other dietary factors like energy density and hyper-palatability.

Don't rely on low-carb or low-fat diets to magically regulate your hunger through hormones. This study shows that even when hormones change significantly, they don't dictate how much you eat if other factors like energy density and taste are present. Focus on the physical properties of food (volume, density) rather than just the macronutrient ratio for short-term intake control.